MX2012015260A - Imidazoles 2-piridil-sustituidos como inhibidores terapeuticos de alk5 y/o alk4. - Google Patents

Imidazoles 2-piridil-sustituidos como inhibidores terapeuticos de alk5 y/o alk4.

Info

Publication number
MX2012015260A
MX2012015260A MX2012015260A MX2012015260A MX2012015260A MX 2012015260 A MX2012015260 A MX 2012015260A MX 2012015260 A MX2012015260 A MX 2012015260A MX 2012015260 A MX2012015260 A MX 2012015260A MX 2012015260 A MX2012015260 A MX 2012015260A
Authority
MX
Mexico
Prior art keywords
pyridyl substituted
substituted imidazoles
alk5
alk4
inhibitors
Prior art date
Application number
MX2012015260A
Other languages
English (en)
Inventor
Dae Kee Kim
Yhun Yhong Sheen
Cheng Hua Jin
Chul-Yong Park
Domalapally Sreenu
Kota Sudhakar Rao
Maddeboina Krishnaiah
Vura Bala Subrahmanyam
Original Assignee
Univ Ewha Ind Collaboration
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ewha Ind Collaboration filed Critical Univ Ewha Ind Collaboration
Publication of MX2012015260A publication Critical patent/MX2012015260A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)

Abstract

Esta invención se refiere a imidazoles 2-piridil-sustituidos, que son inhibidores del receptor de tipo I (ALK5) del factor beta de desarrollo transformante (TGF-ß) y/o del receptor tipo I de activina (ALK4); a métodos para su preparación y a su uso en medicina, específicamente en el tratamiento y la prevención de un estado de enfermedad mediado por esos receptores.
MX2012015260A 2010-06-29 2011-06-24 Imidazoles 2-piridil-sustituidos como inhibidores terapeuticos de alk5 y/o alk4. MX2012015260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/826,338 US8080568B1 (en) 2010-06-29 2010-06-29 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
PCT/KR2011/004631 WO2012002680A2 (en) 2010-06-29 2011-06-24 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors

Publications (1)

Publication Number Publication Date
MX2012015260A true MX2012015260A (es) 2013-04-03

Family

ID=45219191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015260A MX2012015260A (es) 2010-06-29 2011-06-24 Imidazoles 2-piridil-sustituidos como inhibidores terapeuticos de alk5 y/o alk4.

Country Status (24)

Country Link
US (2) US8080568B1 (es)
EP (2) EP2947081B1 (es)
JP (1) JP5732131B2 (es)
KR (1) KR101500665B1 (es)
CN (1) CN103025731B (es)
AU (1) AU2011272149B2 (es)
BR (1) BR112012033334B1 (es)
CA (1) CA2803577C (es)
CO (1) CO6620028A2 (es)
DK (2) DK2947081T3 (es)
ES (2) ES2535876T7 (es)
HK (1) HK1183307A1 (es)
HR (1) HRP20171829T1 (es)
HU (1) HUE036385T2 (es)
IL (1) IL223744A (es)
MX (1) MX2012015260A (es)
PL (1) PL2588479T6 (es)
PT (2) PT2588479E (es)
RS (1) RS56710B1 (es)
RU (1) RU2518069C1 (es)
SG (1) SG186773A1 (es)
UA (1) UA106136C2 (es)
WO (1) WO2012002680A2 (es)
ZA (1) ZA201208662B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
EP3685848B1 (en) 2013-11-21 2021-09-15 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
ES2704027T3 (es) * 2014-05-02 2019-03-13 Lee Sheau Long Uso de ginsenósido M1 para el tratamiento de nefritis lúpica
JP6626094B2 (ja) * 2014-05-16 2019-12-25 ウェルヘッド バイオロジカル テクノロジー コーポレイション 腎線維症を抑制するためのジンセノサイドｍ１の使用
EP3174550B1 (en) 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
TWI582083B (zh) 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
WO2016126028A1 (en) * 2015-02-04 2016-08-11 Medpacto Inc. Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same
WO2016163754A1 (en) * 2015-04-07 2016-10-13 Medpacto Inc. Pharmaceutical composition for preventing or treating cancer and method using thereof
KR20160120157A (ko) * 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
EP3390406A1 (en) 2015-12-15 2018-10-24 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
AU2017284124B2 (en) * 2016-06-13 2021-06-03 Genfleet Therapeutics (Shanghai) Inc. Benzotriazole-derived α and β unsaturated amide compound used as TGF-βR1 inhibitor
KR102434226B1 (ko) 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
EP3492461A4 (en) 2016-07-29 2020-02-12 Shanghai Yingli Pharmaceutical Co. Ltd. NITROGEN HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF
EP3527570A4 (en) * 2016-10-14 2020-04-15 Jiangsu Hengrui Medicine Co., Ltd. FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF
CA3043383A1 (en) 2016-11-14 2018-05-17 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof
CN109983015B (zh) * 2017-03-22 2021-09-03 江苏恒瑞医药股份有限公司 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用
US11124509B2 (en) 2017-03-23 2021-09-21 Clavius Pharmaceuticals, LLC. Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
RU2750702C1 (ru) * 2017-12-13 2021-07-01 Джинфлит Терапьютикс (Шанхай) Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА И СОЛЕВАЯ ФОРМА ИНГИБИТОРА TGF-βRI И СПОСОБ ИХ ПОЛУЧЕНИЯ
EP3725313A4 (en) * 2017-12-13 2021-11-24 The Doshisha COMPOSITION OR PROCESS INCLUDING (T) EW-7197 FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF CORNEAL ENDOTHELIAL DISEASES
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
BR112021007006A2 (pt) 2018-12-27 2021-08-10 Nexys Therapeutics, Inc. derivados de (piridin-2-il)amina como inibidores de tgf-beta r1(alk5) para o tratamento de câncer
JP7335344B2 (ja) * 2019-01-22 2023-08-29 ビシケム カンパニー リミテッド Ａｌｋ４／５阻害剤としての縮合環ヘテロアリール化合物
KR102035481B1 (ko) 2019-04-12 2019-10-23 한국지질자원연구원 점토광물 복합체를 포함하는 염증성 대장염의 예방, 개선 및 치료용 조성물
EP3999501A1 (en) * 2019-07-16 2022-05-25 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
AU2021223336A1 (en) 2020-02-19 2022-10-06 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof
CN114437061B (zh) * 2020-10-30 2023-09-12 陕西莱特光电材料股份有限公司 双酮类化合物的制备方法和咪唑类衍生物的制备方法
CN112266378B (zh) * 2020-11-09 2021-10-12 延边大学 含吲唑结构的咪唑类衍生物及其制备方法和应用
US20230047393A1 (en) * 2021-08-02 2023-02-16 EWHA DrugDesignHouse Co.,Ltd. Composition containing an alk5 inhibitor, ew-7197
KR102509625B1 (ko) * 2022-03-25 2023-03-14 주식회사 메드팩토 TGF-β 저해제의 합성에 유용한 중간체 및 이를 이용한 TGF-β 저해제 제조방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775762A (en) * 1987-05-11 1988-10-04 The Dow Chemical Company Novel (1H-1,2,3-triazol-1-yl)pyridines
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp Triarylimidazole
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JPWO2002096875A1 (ja) 2001-05-25 2004-09-09 持田製薬株式会社 鎮痛作用を有する４−ヒドロキシピペリジン誘導体
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
PL375980A1 (en) * 2002-09-18 2005-12-12 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
EA008881B1 (ru) * 2003-10-24 2007-08-31 Эли Лилли Энд Компани Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
US20080319012A1 (en) * 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AR058807A1 (es) * 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
KR20080082618A (ko) 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절

Also Published As

Publication number Publication date
UA106136C2 (uk) 2014-07-25
BR112012033334B1 (pt) 2020-03-24
US8080568B1 (en) 2011-12-20
SG186773A1 (en) 2013-02-28
EP2588479A4 (en) 2013-11-20
EP2588479B3 (en) 2017-03-29
ES2651499T3 (es) 2018-01-26
EP2588479B1 (en) 2015-03-04
DK2588479T3 (en) 2015-04-07
PL2588479T6 (pl) 2017-10-31
DK2947081T3 (en) 2017-12-04
JP2013533252A (ja) 2013-08-22
DK2588479T6 (en) 2017-05-22
CA2803577C (en) 2015-10-20
KR20130028749A (ko) 2013-03-19
CN103025731A (zh) 2013-04-03
BR112012033334A2 (pt) 2016-11-29
WO2012002680A3 (en) 2012-04-26
RS56710B1 (sr) 2018-03-30
US20110319406A1 (en) 2011-12-29
PT2588479E (pt) 2015-03-26
HUE036385T2 (hu) 2018-07-30
RU2518069C1 (ru) 2014-06-10
EP2588479A2 (en) 2013-05-08
WO2012002680A2 (en) 2012-01-05
PL2588479T3 (pl) 2015-10-30
ES2535876T7 (es) 2017-07-25
AU2011272149A1 (en) 2013-01-17
HK1183307A1 (zh) 2013-12-20
AU2011272149B2 (en) 2014-05-22
ZA201208662B (en) 2013-09-25
PT2947081T (pt) 2017-12-12
USRE47122E1 (en) 2018-11-13
HRP20171829T1 (hr) 2018-02-23
IL223744A (en) 2017-04-30
JP5732131B2 (ja) 2015-06-10
EP2947081B1 (en) 2017-10-18
EP2947081A1 (en) 2015-11-25
CO6620028A2 (es) 2013-02-15
CN103025731B (zh) 2016-01-13
CA2803577A1 (en) 2012-01-05
ES2535876T3 (es) 2015-05-18
KR101500665B1 (ko) 2015-03-09

Similar Documents

Publication Publication Date Title
MX2012015260A (es) Imidazoles 2-piridil-sustituidos como inhibidores terapeuticos de alk5 y/o alk4.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX369576B (es) Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4.
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX361218B (es) Análogos de spliceostatina.
UA115231C2 (uk) Сполуки імідазопіролідинонів
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
IN2012DN02081A (es)
MX349004B (es) Nuevos compuestos.
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX339460B (es) Derivados de benzazol como ligandos del receptor h4 de histamina.
MX355072B (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
TN2013000420A1 (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2012015112A (es) Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
MD20140001A2 (ro) Modulatori alosterici pozitivi ai receptorului nicotinic al acetilcolinei
WO2011091401A9 (en) Treatment of immune disorders using kainate receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration